Test Arm for Type 2 Diabetes (NOVO-GLP1 Trial)

"The most common use for Test Arm is to help people manage their weight over the long term. Additionally, it can be used as part of a treatment plan that includes diet and exercise changes to mitigate other obesity-related health concerns."

"This study allows for patients that are between 18-75 years old, as these are the age limits set in the eligibility criteria."

"The safety of Test Arm is estimated to be a 3. This can be attributed to the fact that this treatment is approved because it is a Phase 4 trial."

"Candidates that have type 2 diabetes mellitus and are aged between 18 to 75 years old may qualify for this clinical trial. The study intends to enroll 126 patients in total."

"Test Arm is being used in 58 different ongoing studies, located across 769 cities and 55 countries. The first study using Test Arm was completed in 2018 as part of Novo Nordisk A/S's Phase 4 drug approval stage. That trial involved 1387 patients. In the years since 2018, 18403 trials have been completed worldwide."

"The listing on clinicaltrials.gov supports that this research is ongoing and seeking patients. The trial was established on August 25th, 2021 with the most recent update being September 9th, 2021. They are looking for 126 individuals total across 1 centre."

"Yes, this trial is currently seeking patients. According to the listings on clinicaltrials.gov, the initial posting was on 8/25/2021 with a most recent update of 9/9/2021. The trial needs 126 total subjects and is only looking at 1 site right now."

"Currently, there are 27 phase 3 trials and 58 active studies investigating Test Arm. Many of these clinical tests for Test Arm are based in Loma Linda, California; however, there are 3901 locations conducting trials for Test Arm."